Patents by Inventor Michael Schwendinger
Michael Schwendinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346906Abstract: The present application relates generally to cancer treatment strategies using arenavirus particles. The treatment strategies described herein are for treating cancer, including head and neck squamous cell carcinoma, using tri-segmented arenavirus particles encoding a human papillomavirus (HPV) antigen. The treatment strategies described herein can include administration of an immune checkpoint inhibitor.Type: ApplicationFiled: May 12, 2021Publication date: November 2, 2023Inventors: Igor MATUSHANSKY, Andy HWANG, Kianoosh KATCHAR, Donna EDWARDS, Henning LAUTERBACH, Michael SCHWENDINGER, Klaus ORLINGER, Sarah SCHMIDT, Ursula BERKA, Katia SCHLIENGER, Corinne IACOBUCCI
-
Publication number: 20230086859Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 29, 2022Publication date: March 23, 2023Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 11407790Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: April 30, 2020Date of Patent: August 9, 2022Assignee: HOOKIPA BIOTECH GMBHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 11305000Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: January 19, 2018Date of Patent: April 19, 2022Assignees: Brookhaven Science Associates, LLC, The Research Foundation of State University of New York, Baxalta Incorporated, Baxalta GmbHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20210024584Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses.Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: April 30, 2020Publication date: January 28, 2021Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 10669315Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: June 9, 2016Date of Patent: June 2, 2020Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Publication number: 20180296656Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: January 19, 2018Publication date: October 18, 2018Applicants: BROOKHAVEN SCIENCE ASSOCIATE, LLC, RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORKInventors: Brian A. Crowe, Ian Livey, Maria O'rourke, Michael Schwendinger, John J Dunn, Benjamin J Luft
-
Publication number: 20180179257Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 9, 2016Publication date: June 28, 2018Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 9895434Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: February 22, 2016Date of Patent: February 20, 2018Assignees: Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20160235830Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: February 22, 2016Publication date: August 18, 2016Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 9334311Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: May 10, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 9303073Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: November 12, 2013Date of Patent: April 5, 2016Assignees: BAXALTA INCORPORATED, BAXALTA GMBH, Research Foundation of the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20140141030Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER INTERNATIONAL INC., Brookhaven Science Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE SAInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20140141029Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 8623376Abstract: The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Research Foundation for the State University of New York, Brookhaven Science Associates, LLCInventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Patent number: 8623375Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: GrantFiled: May 13, 2011Date of Patent: January 7, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Publication number: 20120020973Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: January 26, 2012Applicants: BAXTER INTERNATIONAL INC., Brookhaven Sciences Associates, LLC, Research Foundation of the State University of New York, BAXTER HEALTHCARE S.A.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger, John J. Dunn, Benjamin J. Luft
-
Publication number: 20110293652Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.Type: ApplicationFiled: May 13, 2011Publication date: December 1, 2011Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Brian A. Crowe, Ian Livey, Maria O'Rourke, Michael Schwendinger
-
Patent number: 6291239Abstract: A monoclonal antibody (FE8) against human complement receptor type 2 CR2, CD21) which is able to substantially remove C3-derived fragments already attached to CR2, in particular C3dg from CR2 at temperatures of 25° C. and above. Furthermore, the invention covers hybridoma cells and processes to obtain antibodies, as well as therapeutic applications.Type: GrantFiled: March 25, 1999Date of Patent: September 18, 2001Inventors: Wolfgang Prodinger, Michael Schwendinger